Pretreatment systemic immune-inflammation index can predict response to neoadjuvant chemotherapy in cervical cancer at stages IB2-IIB

Simple item page
dc.contributor.authorLiu, Pingping
dc.contributor.authorJiang, Yinan
dc.contributor.authorZheng, Xiaojing
dc.contributor.authorPan, Baoyue
dc.contributor.authorXiang, Huiling
dc.contributor.authorZheng, Min
dc.date.accessioned2023-03-09T05:23:04Z
dc.date.available2023-03-09T05:23:04Z
dc.date.issued2022-04-27
dc.description.abstractBackground: The systemic immune-inflammation index (SII) has been identified as a predictor of chemotherapy efficacy for a variety of cancers, and we aimed to determine its ability to predict the response to chemotherapy and its long-term prognosis for patients with cervical squamous cell carcinoma (CSCC) who have underwent platinum-based neoadjuvant chemotherapy (NACT). Methods: The date from 210 patients (133 in the training cohort and 77 in the validation cohort) with CSCC who received NACT were analyzed retrospectively. The association between SII and the pathological complete response (pCR) was determined using Pearson’s chi-square test, receiver operating characteristic (ROC) curve, and Logistic regression analysis. The Kaplan-Meier method and Cox proportional regression model were used to assess the relationship between SII and progression-free survival (PFS) or overall survival (OS). Results: The calculated optimal SII cutoff values for pCR and survival were 568.7051 and 600.5683, respectively, and patients were divided into two groups: a low SII group (≤568.7051 or ≤600.5683) and a high SII group (>568.7051 or >600.5683). A high SII was associated significantly with a lower pCR. Further analysis determined that SII was a more efficient predictor of pCR than the prognostic nutritional index, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio. Upon multivariate logistic analysis, SII proved to be an independent risk factor to predict the pCR of patients with CSCC. Kaplan-Meier analysis demonstrated that PFS and OS rates were significantly higher in the low-SII group compared with those in the high-SII group. Additional multivariate analysis indicated that the SII is an independent prognostic factor for patients with CSCC treated with NACT. Conclusion: The results confirmed that the pre-treatment SII is not only an independent predictor of pCR but also an independent prognostic factor of CSCC patients treated with platinum based NACT.en_US
dc.identifier.citationLiu, P., Jiang, Y., Zheng, X., Pan, B., Xiang, H., & Zheng, M. (2022). Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB. Pathology oncology research : POR, 28, 1610294. https://doi.org/10.3389/pore.2022.1610294en_US
dc.identifier.otherDOI: 10.3389/pore.2022.1610294
dc.identifier.urihttps://hdl.handle.net/20.500.14041/6068
dc.language.isoen_USen_US
dc.publisherPathology Oncology Research : PORen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectCervical Canceren_US
dc.subjectPrognosisen_US
dc.subjectNeoadjuvant Chemotherapyen_US
dc.subjectPathological Complete Responseen_US
dc.subjectSystemic Immune-Inflammation Indexen_US
dc.titlePretreatment systemic immune-inflammation index can predict response to neoadjuvant chemotherapy in cervical cancer at stages IB2-IIBen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
pore-28-1610294.pdf
Size:
1.24 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.65 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
SRHR Evidence (Best practice, Systematic reviews)